Oncology (Pediatrics)
Thrombocytopenia Management
Eltrombopag for secondary failure of platelet recovery post-allogeneic hematopoietic stem cell transplant in children. (opens new window)
Source: Pediatr Transplant 2017;21(6):e13017.
Indexed: PubMed 28653480
DOI: 10.1111/petr.13017
https://www.ncbi.nlm.nih.gov/pubmed/28653480 (opens new window)
The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. (opens new window)
Source: Leuk Lymphoma 2007;48(1):9-15.
Indexed: PubMed 17325843
DOI: 10.1080/10428190600909115
https://www.ncbi.nlm.nih.gov/pubmed/17325843 (opens new window)
Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. (opens new window)
Source: Lancet 2003;361(9354):275-80.
Indexed: PubMed 12559860
https://www.ncbi.nlm.nih.gov/pubmed/12559860 (opens new window)
Romiplostim for immune thrombocytopenia in neuroblastoma patients receiving chemotherapy. (opens new window)
Source: J Pediatr Hematol Oncol 2019;41(4):e257-9.
Indexed: PubMed 29683946
DOI: 10.1097/MPH.0000000000001187
https://www.ncbi.nlm.nih.gov/pubmed/29683946 (opens new window)
Romiplostim for therapy-related thrombocytopenia in pediatric malignancies. (opens new window)
Source: Pediatr Blood Cancer 2017;64(8):e26473.
Indexed: PubMed 28150377
DOI: 10.1002/pbc.26473
http://www.ncbi.nlm.nih.gov/pubmed/28150377 (opens new window)
Eltrombopag for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation in children. (opens new window)
Source: J Pediatr Hematol Oncol 2019;41(1):38-41.
Indexed: PubMed 30080752
DOI: 10.1097/MPH.0000000000001263
https://www.ncbi.nlm.nih.gov/pubmed/30080752 (opens new window)
Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children. (opens new window)
Source: Int J Hematol 2015;102(5):626-32.
Indexed: PubMed 26084627
DOI: 10.1007/s12185-015-1821-1
https://www.ncbi.nlm.nih.gov/pubmed/26084627 (opens new window)
Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. (opens new window)
Source: J Pediatr 1996;129(5):656-60.
Indexed: PubMed 8917229
DOI: 10.1016/s0022-3476(96)70145-2
https://www.ncbi.nlm.nih.gov/pubmed/8917229 (opens new window)
Chemotherapy induced thrombocytopenia in pediatric oncology. (opens new window)
Source: Crit Rev Oncol Hematol 2016;99:299-307.
Indexed: PubMed 26811139
DOI: 10.1016/j.critrevonc.2016.01.005
https://www.ncbi.nlm.nih.gov/pubmed/26811139 (opens new window)
Oncological management of pediatric cancer patients belonging to Jehovahs Witnesses: a two-institutional experience report. (opens new window)
Source: Onkologie 2004;27(2):131-7.
Indexed: PubMed 15138344
DOI: 10.1159/000076901
https://www.ncbi.nlm.nih.gov/pubmed/15138344 (opens new window)
Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. (opens new window)
Source: Ann Oncol 2005;16(1):139-45.
Indexed: PubMed 15598951
DOI: 10.1093/annonc/mdi007
https://www.ncbi.nlm.nih.gov/pubmed/15598951 (opens new window)
Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. (opens new window)
Source: Blood 1998;91(10):3601-6.
Indexed: PubMed 9572994
https://www.ncbi.nlm.nih.gov/pubmed/9572994 (opens new window)